Your browser doesn't support javascript.
loading
Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage.
Pourebrahim, Rasoul; Montoya, Rafael Heinz; Alaniz, Zoe; Ostermann, Lauren; Lin, Patrick P; Liu, Bin; Ayoub, Edward; Burks, Jared K; Andreeff, Michael.
  • Pourebrahim R; MD Anderson Cancer Center.
  • Montoya RH; MD Anderson Cancer Center.
  • Alaniz Z; MD Anderson Cancer Center.
  • Ostermann L; MD Andreson Cancer Center.
  • Lin PP; MD Anderson Cancer Center.
  • Liu B; Epigenetic and Molecular Carcinogenesis.
  • Ayoub E; Leukemia.
  • Burks JK; Leukemia.
  • Andreeff M; The University of Texas MD Anderson Cancer Center.
Res Sq ; 2023 Mar 02.
Article en En | MEDLINE | ID: mdl-36909480
ABSTRACT
Mesenchymal stromal cells (MSCs) are a key component of the bone marrow (BM) niche, providing essential support required for maintenance of hematopoietic stem cells. To advance our understanding of physiological functions of p53 and Mdm2 in BM-MSCs, we developed traceable conditional mouse models targeting Mdm2 and/or Trp53 in vivo . We demonstrate that Mdm2 is essential for the emergence, maintenance and hematopoietic support of BM-MSCs. Mdm2 haploinsufficiency in BM-MSCs resulted in genotoxic stress-associated thrombocytopenia, suggesting a functional role for Mdm2 in hematopoiesis. In a syngeneic mouse model of acute myeloid leukemia (AML), Trp53 deletion in BM-MSCs improved survival, and protected BM against hematopoietic toxicity from a murine Mdm2i, DS-5272. The transcriptional changes were associated with dysregulation of glycolysis, gluconeogenesis, and Hif-1α in BM-MSCs. Our results reveal a physiologic function of Mdm2 in BM-MSC, identify a previously unknown role of p53 pathway in BM-MSC-mediated support in AML and expand our understanding of the mechanism of hematopoietic toxicity of MDM2is.